Clinical Trial

Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The investigators propose a stepwise screening approach. The first step involves rapid digital pre-screening of cognitive function through three components: the SCD-9 questionnaire to capture subjective cognitive complaints, a digital cognitive assessment to evaluate objective performance, and a predictive model to estimate future dementia risk in cognitively normal individuals. The second step confirms the presence of AD pathology using blood-based biomarkers, with a head-to-head comparison of multiple novel candidates to identify those with the greatest diagnostic utility.
Trial Details
NCT Number NCT07284264
Lead Sponsor Xuanwu Hospital, Beijing
Conditions Dementia
Enrollment 6,000 participants
Start Date 2025-08-15
Primary Completion 2026-01-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-16